MIRM
MIRM clinical trials: Mirum Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Mirum Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 43
- Trials linked
- 40
- As lead sponsor
- 3
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
MIRM on the catalyst calendar · MIRM registry changes
- Primary completion Feb 20, 2026ActualPhase 2NCT04663308A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing...Mirum Pharmaceuticals, Inc. · Primary Sclerosing CholangitisActive, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 29, 2026ActualPhase 3NCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Mirum Pharmaceuticals, Inc. · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)Active, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 20, 2028Sponsor estimateNo phase registeredNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc. · Alagille SyndromeRecruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07922733Expanded-Access Program for the Treatment of Chronic Hepatitis D With BrelovitugMirum Pharmaceuticals, Inc. · Chronic Hepatitis, Delta VirusAvailableMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2027Sponsor estimatePhase 2/Phase 3NCT07454837Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc. · Chronic Hepatitis DRecruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2029Sponsor estimatePhase 2/Phase 3NCT06907290A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionMirum Pharmaceuticals, Inc. · Chronic Hepatitis D InfectionActive, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2026ActualPhase 1NCT07712718A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379Mirum Pharmaceuticals, Inc. · Healthy VolunteersCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2027Sponsor estimatePhase 3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc. · Chronic Hepatitis D InfectionRecruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 2NCT07209462Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)Mirum Pharmaceuticals, Inc. · Fragile X SyndromeRecruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2029Sponsor estimatePhase 2NCT07823127MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy...Mirum Pharmaceuticals, Inc. · Intrahepatic Cholestasis of PregnancyNot yet recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT05050136A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary...Mirum Pharmaceuticals, Inc. · Primary Biliary CholangitisActive, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2038Sponsor estimateNo phase registeredNCT03115086The REPLACE Registry for Cholbam® (Cholic Acid)Mirum Pharmaceuticals, Inc. · Bile Acid Synthesis DisordersActive, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2026Sponsor estimatePhase 3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc. · Chronic Hepatitis D InfectionActive, not recruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2030Sponsor estimatePhase 4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive...Mirum Pharmaceuticals, Inc. · Alagille SyndromeRecruitingMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2024ActualPhase 2NCT04729751A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including...Mirum Pharmaceuticals, Inc. · Progressive Familial Intrahepatic CholestasisCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2025ActualPhase 3NCT04185363An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)Mirum Pharmaceuticals, Inc. · Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2024ActualPhase 2NCT04168385MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated...Mirum Pharmaceuticals, Inc. · Cholestatic Liver DiseaseCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2023ActualPhase 2NCT04524390Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiMirum Pharmaceuticals, Inc. · Biliary AtresiaCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2023ActualPhase 3NCT04270682Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)Mirum Pharmaceuticals, Inc. · CTXCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2022ActualPhase 2NCT04718961A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy...Mirum Pharmaceuticals, Inc. · Intrahepatic Cholestasis of PregnancyTerminatedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2022ActualPhase 3NCT03905330A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)Mirum Pharmaceuticals, Inc. · Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2020ActualPhase 2NCT02057718Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in...Mirum Pharmaceuticals, Inc. · Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 3NCT01438411Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid SynthesisMirum Pharmaceuticals, Inc. · Bile Acid Synthesis DefectCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2010ActualPhase 3NCT01115582Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisMirum Pharmaceuticals, Inc. · Inborn Errors of Bile Acid SynthesisCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009ActualPhase 3NCT00007020Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidMirum Pharmaceuticals, Inc. · Infantile Refsum's DiseaseCompletedMIRMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 18 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner